Used in the treatment of complex bifurcation lesions

Cappella, a developer of treatment for coronary bifurcated disease, has reported that its Sideguard Coronary Sidebranch Stent and Delivery System has treated first patient in UK. The initial case was performed at PCI Live 2009 with the second case following immediately thereafter, off-camera.

Dr. Joseph Mills, consultant Cardiologist at the Liverpool Heart and Chest Hospital, UK performed both the procedures.

Dr. Mills said: “We see numerous bifurcation cases and are very pleased to see that there is now a dedicated and straightforward solution to treating complex bifurcation lesions. As the first centre in the UK to use Sideguard, we are very satisfied with the results.”

Cappella recently added an additional size of 3.25 to their current portfolio of 2.5 and 2.75. This currently enables treatment of bifurcation lesions in lumen diameters from 2.25 to 3.25mm and lesion lengths less than or equal to 7mm.

In addition to the new diameter, the product line will be further expanded.

Dr. Art Rosenthal, CEO of Cappella, said: “We will make longer-length stents available in 2010, enhancing our broad product line and Cappella’s position as the leading company in the treatment of bifurcations.”

Cappella also expanded its commercial operations in Europe with the addition of a direct sales force this past month for the UK and Ireland. The company is currently active in Germany, Italy, the Netherlands, Austria and Switzerland.